MedWatch

Danske Capital anticipates more acquisitions: "The troll is out of the box"

Various factors currently make biotech firms attractive acquisitions for the large drug groups, says senior portfolio manager in Danske Capital. He expects Bristol-Myers Squibb's billion-dollar acquisition of Celgene to be followed by more deals.

Foto: Colourbox

Bristol-Myers Squibb (BMS) was first with mergers and acquisitions in the pharma industry in 2019. Already on January 3, the US drug group announced that it acquires Celgene for USD 74 billion.

And the beginning of the year will bring about more deals like this, predicts Claus Henrik Johansen, Senior Portfolio Manager in Danish asset manager Danske Capital. He attended last week's JP Morgan Healthcare Conference in San Fransisco, US, and listened to presentations from several major actors in the pharma industry.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Headhunter: Afgående Leo-boss var et flop

Det var et fejlskud at ansætte Catherine Mazzacco som adm. direktør for Leo Pharma, vurderer headhunter, der ser afgangen som et naturligt skridt forud for børsnoteringen af Leo Pharma. Til at styre den proces i mål vil bestyrelsen efter alt at dømme skulle til udlandet for at finde den rette profil, lyder det videre.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier